Tandem Diabetes Care Inc (TNDM) Receives Average Rating of “Hold” from Analysts
Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) have earned an average recommendation of “Hold” from the seven ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $13.00.
Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Wednesday. Robert W. Baird reaffirmed a “hold” rating and set a $3.00 target price on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $15.00 target price on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $17.00 target price (down from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th.
In other news, CEO Kim D. Blickenstaff purchased 285,700 shares of the stock in a transaction on Friday, October 13th. The stock was bought at an average price of $3.50 per share, for a total transaction of $999,950.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.90% of the stock is owned by corporate insiders.
Shares of Tandem Diabetes Care (NASDAQ TNDM) opened at $2.48 on Thursday. Tandem Diabetes Care has a 52 week low of $2.15 and a 52 week high of $30.00. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share for the quarter, topping the consensus estimate of ($3.74) by $0.65. Tandem Diabetes Care had a negative net margin of 79.45% and a negative return on equity of 1,177.11%. The firm had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.92 million. During the same period in the prior year, the firm earned ($0.97) EPS. The firm’s revenue for the quarter was up 119.7% on a year-over-year basis. equities research analysts expect that Tandem Diabetes Care will post -15.37 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Tandem Diabetes Care Inc (TNDM) Receives Average Rating of “Hold” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/14/tandem-diabetes-care-inc-tndm-receives-average-rating-of-hold-from-analysts.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.